Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 dichloride access and safety study in castration-resistant prostate cancer with bone metastases
NL-OMON39188Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of radium-223 dichloride in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Primary endpoints: Acute and long-term safety of radium-223 dichloride and Overall survival. Started Oct 2013; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON39188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39188.